05-06-2026 09:56 via prnewswire.com

AeroVironment, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AVAV

LOS ANGELES, June 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AeroVironment, Inc. ("AeroVironment" or "the Company") (NASDAQ: AVAV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...
Read more »

PR Public relations news



Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
CERAVE VÍTA NA PRVÝCH GLOBÁLNYCH CENÁCH CERAWARDS VIAC AKO 100 OCENENÝCH TVORCOV OBSAHU Z 22 KRAJÍN
CERAVE VÍTA NA PRVÝCH GLOBÁLNYCH CENÁCH CERAWARDS VIAC AKO 100 OCENENÝCH TVORCOV OBSAHU Z 22 KRAJÍN
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
MimiSilk marque 12 ans de soins avancés avec le lancement de nouveaux produits et une vente anniversaire
MimiSilk marque 12 ans de soins avancés avec le lancement de nouveaux produits et une vente anniversaire
MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
MimiSilk Marks 12 Years of Advanced Care with New Product Launches and Anniversary Sale
MimiSilk feiert 12 Jahre fortschrittliche Pflege mit neuen Produkten und Jubiläumsverkauf
MimiSilk feiert 12 Jahre fortschrittliche Pflege mit neuen Produkten und Jubiläumsverkauf
Desktop versie